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Homocysteine (Hcy) plasma level is an independent risk marker for venous thrombosis, myocardial infarction,
stroke, congestive heart failure, osteoporotic fractures, and Alzheimer disease. Hcy levels are determined by the
interaction of genetic and environmental factors. The genetic basis is still poorly understood, since only the MTHFR
677 CrT polymorphism has been consistently associated with plasma Hcy levels. We conducted a genomewide
linkage scan for genes affecting variation in plasma Hcy levels in 398 subjects from 21 extended Spanish families.
A variance-components linkage method was used to analyze the data. The strongest linkage signal (LOD score of
3.01; genomewide P p .035) was found on chromosome 11q23, near marker D11S908, where a candidate gene
involved in the metabolism of Hcy (the nicotinamide N-methyltransferase gene [NNMT]) is mapped. Haplotype
analyses of 10 single-nucleotide polymorphisms within this gene found one haplotype associated with plasma Hcy
levels (P p .0003). Our results, to our knowledge, represent the first genomic scan for quantitative variation in
Hcy plasma levels. They strongly suggest that the NNMT gene could be a major genetic determinant of plasma
Hcy levels in Spanish families. Since this gene encodes an enzyme involved in Hcy synthesis, this finding would be
consistent with known biochemical pathways. These data could be relevant in determining the relationships between
Hcy level, cardiovascular disease, osteoporosis, and Alzheimer disease.
Introduction
Multiple case-control and prospective studies have es-
tablished an association between moderate hyperhomo-
cysteinemia and increased risk of ischemic heart disease
and stroke (Welch and Loscalzo 1998; Cattaneo 1999;
Homocysteine Studies Collaboration 2002; Wald et al.
2002), congestive heart failure (Vasan et al. 2003), and
deep vein thrombosis (Cattaneo 1999). Furthermore, re-
cent data from the Framingham Study indicate that
plasma homocysteine (Hcy) level is also a dose-related
risk marker for the development of dementia and Alz-
heimer disease (Seshadri et al. 2002). There have been
additional reports on the association between hyper-
homocysteinemia and Alzheimer disease (Morris 2003),
mental deterioration (Morris et al. 2001), and vascular
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dementia (McIlroy et al. 2002). These associations seems
to be independent of age, sex, apolipoprotein E gene
(APOE) genotype, plasma vitamin levels, and other pu-
tative risk factors (Seshadri et al. 2002). Furthermore,
elevated Hcy concentration has been associated with risk
of osteoporotic fractures in elderly persons (McLean et
al. 2004; van Meurs et al. 2004)
The plasma Hcy level is a quantitative phenotype that
is influenced by genetic and environmental factors. The
main environmental determinants are sex, age, renal
function, and vitamin intake (Brattsstro¨m et al. 1994).
However, the genetic component is still poorly under-
stood. Currently, the most widely accepted polymor-
phism associated with Hcy variability is MTHFR 677
CrT (Frosst et al. 1995). Other common polymor-
phisms within genes for enzymes involved in Hcy me-
tabolism have been described. These polymorphisms,
along with MTHFR 677 CrT, account for !10% of
the variance in plasma Hcy level (Kluijtmans et al.
2003). A recent family study, which involved a segre-
gation analysis, suggested the existence of a major gene
that regulates Hcy plasma level, even after adjusting for
effects of MTHFR 677 CrT (Jee et al. 2002).
As part of our Genetic Analysis of Idiopathic Throm-
bophilia (GAIT) Project, we observed that the herita-
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bility of Hcy plasma levels ( SD) was 0.25  0.08,
indicating that ∼25% of the phenotypic variation in this
trait is due to the additive effect of genes (Souto et al.
2000b). Additional results from the GAIT Project
(Souto et al. 2000a) have demonstrated that Hcy levels
are genetically correlated with thrombotic risk (r pG
). This implies that some genes influence simulta-0.65
neously the plasma levels of Hcy and the risk of throm-
boembolic disease.
In an effort to localize the genes influencing variation
in plasma Hcy levels, we conducted a genomewide link-
age scan of DNA from individuals in the GAIT sample.
Material and Methods
Study Population
The GAIT Project includes 21 extended families, 12
of whom were ascertained through a proband with
thrombophilia, and 9 of whom were obtained randomly
from the general population. A total of 398 individuals
were examined, with a mean of 19 individuals examined
per family. The composition of the families and the col-
lection of lifestyle, medical, and family history data have
been detailed elsewhere (Souto et al. 2000b). The study
was performed in accordance with the Declaration of
Helsinki of 1975; all adult patients provided informed
consent and parents of minors provided informed con-
sent for their children. All procedures were approved by
the institutional review board of the Hospital de la Santa
Creu i Sant Pau, Barcelona, Spain.
Plasma Hcy Determination
EDTA blood samples were obtained by venipuncture
after a 12-h fast. Measures to prevent the flow of Hcy
from erythrocytes to plasma were strictly implemented.
Total Hcy plasma concentration was measured by use
of high-performance liquid chromatography (Millipore)
and fluorescence detection (Kontron Instruments). The
analytical characteristics of this method have been an-
alyzed and compared to a widely used commercial im-
munoassay (Blanco-Vaca et al. 2000).
DNA Extraction and Genotype Analysis
DNA extraction was performed in accordance with a
standard protocol (Souto et al. 2000b). Subjects were
genotyped for an autosomal genomewide scan with 363
highly informative DNA markers. Microsatellites con-
sisted primarily of the ABI Prism genotyping set MD-
10 (Applied Biosystems). PCR products were analyzed
on PE 310, PE 377, and PE 3700 automated sequencers
and were genotyped using PE Genotyper software (Ap-
plied Biosystems). The average heterozygosity of the mi-
crosatellite markers was 0.79, and the average distance
between markers was 9.5 cM. The 677 CrT polymor-
phism in the MTHFR gene was genotyped using PCR
with primers described elsewhere (Frosst et al. 1995) and
with minor modifications to the reaction conditions.
Marker maps for multipoint analyses were obtained
from ABI Prism and from the Marshfield Center for
Medical Genetics.
Genetic Linkage Analysis
Levels of Hcy in the GAIT sample exhibited a kurtosis
of 29.5. For this reason, we used a natural logarithm to
transform the Hcy values to achieve a normal distri-
bution, and the new logarithmically transformed Hcy
(lnHcy) levels had a kurtosis of only 0.48. This level of
kurtosis did not affect the distribution of LOD scores
(Blangero et al. 2000). The standard nominal P values
for LOD scores were appropriate for the lnHcy linkage
tests. The calculations also incorporated a simultaneous
correction for covariates like sex, age, and BMI. Esti-
mation of heritability ( ) and the covariate effects of2h
lnHcy were done using methods described elsewhere
(Souto et al. 2000b). All analyses included an ascertain-
ment correction, achieved by conditioning the likelihood
of these pedigrees on the likelihoods of their respective
probands (Boehnke and Lange 1984)
Standard multipoint variance-components linkage
methods were used for the genome scan (Almasy and
Blangero 1998). These methods have been implemented
in the program SOLAR (available at the Southwest
Foundation for Biomedical Research Web site). The sta-
tistical analysis is based on specification of the expected
genetic covariances between arbitrary relatives as a func-
tion of the identity-by-descent (IBD) relationships at a
given marker locus. To estimate the IBD matrix in these
complex pedigrees, we used a Markov chain–Monte
Carlo method as implemented in SIMWALK2 (Sobel
and Lange 1996), which estimates the IBD probabilities
at each cM. Bivariate linkage analyses with the use of a
mixed discrete-/continuous-trait multivariate model
were conducted with a modified version of SOLAR (Wil-
liams et al. 1999)
SNP Identification and Haplotype Analysis
We sequenced the nicotinamide N-methyltransferase
gene (NNMT [UniGene accession number Hs.364345])
in 42 unrelated individuals from the GAIT Project using
standard sequencing methods on an ABI 3100 auto-
mated sequencer (Applied Biosystems). The use of this
number of individuals provided a 199% probability
of detecting any polymorphism that had a frequency
0.05. To enrich the sequencing sample for functional
variants, we chose 22 individuals from those in the
higher tail of the Hcy distribution and 20 from those in
the lower tail. We sequenced ∼1.5 kb of the proximal
promoter of NNMT, including exon 1, and we then con-
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Figure 1 Linkage results from the autosomal multipoint genome scan. LOD score scales are shown for chromosomes 1, 3, 4, 10, and
11—the only chromosomes on which the maximum LOD score was 11. Hatch marks along the length of the chromosomes indicate the positions
of the DNA markers.
tinued with the coding regions of exons 2, 3, 4, and 5.
The latter included the 3′ UTR, with potential regulatory
sequences.
Then, we genotyped the newly identified SNPs in our
whole GAIT sample, as well as all previously reported
NNMT SNPs (from the Celera database, available at the
Applied Biosystems, myScience, Web site), by sequencing
with the use of the SNP Genotyping Assays-on-Demand
products from Applied Biosystems, in accordance with
the recommendations of the manufacturer. The haplo-
types with the SNPs detected in the NNMT gene were
generated with the use of the “best” option in the MER-
LIN program (Abecasis et al. 2002). The association of
each SNP or haplotype with Hcy plasma levels was
tested by use of a quantitative-trait association analysis
with the measured genotype approach, which involved
testing for genotype-specific differences in the mean val-
ues of traits while allowing for the nonindependence
among family members (Almasy and Blangero 2004).
These analyses were performed using SOLAR.
Results
In the GAIT sample, the mean age-corrected Hcy plasma
level ( SD) was 7.8  3.1 mmol/liter. The range of
Hcy values was 2.7–46.6 mmol/liter. After natural-log-
arithm transformation, lnHcy values showed a mean (
SD) of 2.05  0.36. The significant regression coeffi-
cients for the covariates influencing lnHcy were 0.006
for age, 0.12 for female sex, and 0.004 for BMI. To-
gether, they accounted for 18% of the variability of
lnHcy levels. The heritability of the lnHcy phenotype
( SD) was 0.34  0.08. This shows that genes play
an important role in determining plasma levels (34% of
phenotypic variability). This result is consistent with the
previous estimate of for crude values2h p 0.25 0.08
of Hcy (Souto et al. 2000b).
Effects of the MTHFR 677 CrT Polymorphism
The 677 CrT variant was present in 20 GAIT fam-
ilies. There were 174 heterozygotes and 59 homozygotes
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Table 1
Genes Involved in Hcy Metabolism, with Their Chromosomal Locations and the Maximum
LOD Score Obtained at Each Locus
Gene Abbreviation Location LOD
Nicotinamide N-methyltransferase NNMT 11q23 3.01
Methionine adenosyltransferase a I MATaI 10q22 1.68
Methionine adenosyltransferase a II MATaII 2p11 !1
Methionine adenosyltransferase b MATb 5q34 !1
5,10-Methylenetetrahydrofolate reductase MTHFR 1p36 1.03
Other SAM-dependent methyltransferasesa … … !1
5-Methyltetrahydrofolate-homocysteine methyltransferase MTR 1q43 !1
Methionine synthase reductase MTRR 5p15 !1
Betaine-homocysteine methyltransferase BHMT 5q14 !1
S-adenosylhomocysteine hydrolase AHCY 20q11 !1
Cystathionine b-synthase CBS 21q22 !1
Dihydrofolate reductase DHFR 5q14 !1
Cystathionine g-lyase CTH 1p31 !1
Serine hydroxymethyltransferase 1 SHMT1 17p11 !1
Serine hydroxymethyltransferase 2 SHMT2 11q12 !1
Thymidylate synthase TS 18p11 !1
Methylenetetrahydrofolate dehydrogenase 1 MTHFD1 14q23 !1
Methylenetetrahydrofolate dehydrogenase 2 MTHFD2 2p13 !1
S-adenosylmethionine decarboxylase AMD1 6q21 !1
Choline dehydrogenase CHDH 3p21 !1
Paraoxonase PON1 7q21 !1
Folate receptor FOLR1 11q13 !1
Folate carrier 19 member 1 SLC19A1 21q22 !1
Folate carrier 19 member 2 SLC19A2 1q24 !1
Folate carrier 19 member 3 SLC19A3 2q36 !1
Transcobalamin 1 TCN1 11q12 !1
Transcobalamin 2 TCN2 22q12 !1
Intrinsic factor GIF 11q12 !1
a Apart from NNMT, there exist 38 other human SAM-dependent methyltransferases (Clarke
and Banfield 2001); none of their respective gene loci showed a LOD score 11, and none is
located on 11q23 or 10q22, where we obtained the highest LOD scores in our analysis.
for the T allele, and they exhibited higher mean Hcy
levels than noncarriers (Hcy levels of 7.8 mmol/liter in
CT heterozygotes, 9.5 mmol/liter in TT homozygotes,
and 7.1 mmol/liter in CC noncarriers).
Nominal evidence of linkage was found between
lnHcy levels and the MTHFR locus in a two-point link-
age analysis (LOD score of 0.66; ). Additionally,Pp .04
the 677 CrT polymorphism was strongly associated
with lnHcy levels ( ).5P ! 1.6# 10
Genomewide Linkage Analysis
Multipoint linkage analyses were performed across all
22 autosomes. The results of the genome scan for a QTL
influencing lnHcy levels are shown in figure 1. One re-
gion, on chromosome 11q23, showed strong evidence
of linkage (LOD score of 3.01; nominal ; ge-Pp .0001
nomewide ). This peak was the highest LODPp .035
score found and occurred between markers D11S908
and D11S4142. This suggests that there is a gene in this
region that influences plasma levels of Hcy. The one-unit
support interval surrounding this peak has a chromo-
somal location in the range of 112–118 cM from the p
terminus. This region contains the gene NNMT, which
is involved in Hcy metabolism and is thus a candidate
gene to explain the linkage signal.
Another chromosomal region produced a LOD score
of 1.68 (nominal ), suggesting linkage. The re-Pp .003
gion was on chromosome 10q22 (fig. 1 and table 1),
corresponding to marker D10S537. Such a LOD score
would be expected to occur by chance approximately
once every genome scan and must be considered sug-
gestive until supported by other evidence. Again, there
is a gene within this region that is involved in Hcy me-
tabolism and is a candidate to explain the observed link-
age signal: the methionine adenosyltransferase a I gene
(MATaI).
The maximum LOD score found in the region of the
MTHFR gene on chromosome 1p36.3 was 1.03 (nom-
inal ) (fig. 1 and table 1). These multipointPp .015
results show only a marginal increase from the LOD
score of 0.66 obtained in the two-point linkage analysis
with only the 677 CrT polymorphism as a marker.
Because our previous studies have suggested that Hcy
levels are genetically correlated ( ) with the sus-r p 0.65G
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Table 2
Genotyped SNPs within NNMT and Results from the Association Analysis with Hcy
Plasma Levels
SNP Celera IDa dbSNP ID Location
Positionb
(bp)
Allele
Frequenciesc Pd
1 Newe rs35077908 Promoter 113,632,968 81/19 .38
2 c1058033 rs505978 Intron 1 113,634,267 76/24 .64
3 c1058034 rs683271 Intron 1 113,634,355 77/23 .65
4 c2134722 rs694539 Intron 1 113,638,629 85/15 .017
5 c2134725 rs11214921 Intron 2 113,642,022 19/81 .16
6 c2134727 rs10891641 Intron 2 113,644,291 21/79 .81
7 c10096025 rs2852432 Intron 2 113,669,214 27/73 .49
8 c10096016 rs2852447 Intron 4 113,684,911 75/25 .29
9 Newe rs4646337 3′ UTR 113,688,519 79/21 .98
10 c10096011 rs11569688 3′ UTR 113,688,653 18/81 .64
NOTE.—The SNP with a significant P value ( ) is shown in bold italics.P ! .05
a Celera database available at the Applied Biosystems, myScience, Web site.
b The SNP position from the p terminus of chromosome 11.
c Estimated allele frequencies in the Spanish population, given as percentages (allele
1/allele 2), with family relationships taken into account.
d P value of association with Hcy levels. Values are not corrected for the number of
markers tested.
e “New” indicates that the SNP was found in the present study and was not previously
reported.
ceptibility to thrombosis (Souto et al. 2000a), we per-
formed a bivariate linkage analysis. Bivariate analyses
of related phenotypes have been shown to increase the
power to detect linkage (Soria et al. 2002, 2003). In the
combined analyses of lnHcy levels and thrombosis, the
three LOD scores on chromosomes 11, 10, and 1 re-
mained at their previous levels, with no significant QTL
effects on susceptibility, providing no evidence that these
QTLs influence thrombosis risk. Nevertheless, these re-
sults do not allow the possibility to be excluded.
Screening for SNPs in NNMT and Haplotype
Association Analysis
We identified two novel SNPs. One (SNP 1 in table
2) is in the promoter region, and the other (SNP 9 in
table 2) is in the 3′ UTR. These 2 identified SNPs, to-
gether with 10 SNPs previously reported in 2003 (Celera
database), were genotyped for the whole GAIT sample.
Of these 12 SNPs, 2 were excluded from the analysis
because they correlated (i.e., showed perfect linkage dis-
equilibrium) with other SNPs. The details of the 10 SNPs
included in our analysis are given in table 2.
The measured-genotype association analysis revealed
significant association between one of the SNPs (Celera
accession number c2134722) and Hcy levels (table 2),
supporting the presence of a QTL in the region of
NNMT. In addition, in the GAIT sample, the 10 SNPs
in the NNMT gene generated 31 haplotypes (table 3).
In the measured-genotype association analysis, one of
the haplotypes (Hap 18) was strongly associated with
Hcy levels ( ), even after correction for mul-Pp .00001
tiple testing (corrected ). Two other hap-Pp .00031
lotypes (Hap 22 and Hap 31) showed an association
with Hcy levels ( and .04, respectively), but thePp .01
statistical significance was lost when the results were
corrected for multiple testing. All carriers of Hap 18
( ) were heterozygous and had a mean Hcy levelnp 12
( SD) of 13.2  2.9 mmol/liter.
Discussion
A major challenge for medicine in the postgenomic era
is to identify genetic variants that affect the risk of de-
veloping complex diseases such as cardiovascular or Alz-
heimer disease. It is usually extremely difficult to find
these QTLs when the study focuses directly on disease
status (i.e., disease or no disease). However, intermediate
risk factors or risk markers can be analyzed by a genetic
search. According to recent reports of epidemiological
data, the Hcy plasma level is an independent inter-
mediate risk marker for thromboembolic disease (both
arterial and venous) (Welch and Loscalzo 1998; Catta-
neo 1999; Homocysteine Studies Collaboration 2002;
McIlroy et al. 2002; Wald et al. 2002), congestive heart
failure (Vasan et al. 2003), Alzheimer disease (Morris et
al. 2001; McIlroy et al. 2002; Seshadri et al. 2002; Mor-
ris 2003), and osteoporotic fractures (McLean et al.
2004; van Meurs et al. 2004).
In humans, the sole source of Hcy is the demethy-
lation of methionine through the intervention of differ-
ent methyltransferases. This pathway has several steps
(fig. 2). First, methionine and ATP originate S-adeno-
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Table 3
Haplotypes Observed within the NNMT Gene in the GAIT Sample,
in Order of Frequency
Haplotypea Hap ID Frequencyb
Hcy Levelc
(mmol/liter) Pd
1111222112 Hap 7 318 7.60 .69
2111222221 Hap 30 84 7.51 .99
1222111112 Hap 22 73 6.94 .01
2111222112 Hap 28 58 7.22 .87
1111221112 Hap 4 56 7.92 .89
1221222112 Hap 20 37 7.67 .59
1111222221 Hap 9 30 7.55 .69
1111221221 Hap 6 16 8.30 .09
1221211112 Hap 18 12 13.18 .00001
1222111212 Hap 24 9 7.97 .58
1111221212 Hap 5 8 8.55 .48
1221112112 Hap 16 8 7.64 .77
2111221212 Hap 27 8 9.80 .07
1112112112 Hap 13 7 6.66 .95
1111222212 Hap 8 5 6.42 .68
1112111221 Hap 12 5 8.00 .40
1111211222 Hap 3 4 6.22 .65
1112111212 Hap 11 3 7.10 .85
1221111112 Hap 14 3 10.76 .22
1221111222 Hap 15 3 7.37 .52
1221112221 Hap 17 3 7.00 .75
1221222221 Hap 21 3 6.00 .42
2111222211 Hap 29 3 8.20 .68
2112111112 Hap 31 3 5.10 .04
1111122112 Hap 2 2 10.00 .39
1111222222 Hap 10 2 9.85 .57
1221211222 Hap 19 2 5.90 .85
1222112112 Hap 26 2 5.50 .20
1111111221 Hap 1 1 7.70 .78
1222111122 Hap 23 1 3.90 .38
1222111221 Hap 25 1 8.20 .86
NOTE.—The haplotypes with significant P values ( ) areP ! .05
shown in bold italics.
a The composition of the haplotypes follows the same order of SNPs
as in table 2.
b Frequency is given as the number of chromosomes containing the
haplotype. There were only four haplotypes with homozygous carriers:
Hap 7, Hap 20, Hap 22, and Hap 28. No statistically significant
differences in Hcy levels between heterozygous and homozygous car-
riers were observed.
c Crude mean Hcy levels among haplotype carriers, without ac-
counting for the nonindependence of family members.
d P value of association with Hcy levels. Values are not corrected
for the number of haplotypes tested.
sylmethionine (SAM) by means of the enzyme methi-
onine adenosyltransferase. Then, SAM is converted to
S-adenosylhomocysteine (SAH) in a reaction catalyzed
by SAM-dependent methyltransferases. This reaction
originates a methyl group that is used for many different
biochemical pathways through, in humans, at least 39
distinct methyltransferases (Clarke and Banfield 2001).
SAH is subsequently broken down to form adenosine
and Hcy that is remethylated to form methionine. Al-
ternatively, Hcy can be converted to cysteine through
the transsulfuration pathway.
The majority of potential candidate genes, which en-
code enzymes or proteins involved in Hcy metabolism
(fig. 2 and table 1), did not produce a linkage signal for
Hcy levels. The results of our genome scan suggest that
the major QTL influencing variation in Hcy levels is
located on chromosome 11q23 (fig. 1). Interestingly,
this region has been linked to the risk of venous throm-
bosis in a genome scan performed with a single large
pedigree with thrombosis and protein C deficiency (Has-
stedt et al. 2004). This genetic protein C deficiency ap-
peared insufficient to explain completely the venous
thrombosis risk in the family. For this reason, Hasstedt
et al. (2004) undertook a genomewide search of re-
gions potentially harboring other genetic factors. In the
search, a peak of significance was found at 113 cM from
the p terminus of chromosome 11, just within our sup-
port interval (112–118 cM) for the Hcy QTL. We also
investigated the possible pleiotropic effect of this QTL
on the risk of thrombosis. The linkage signal in the
bivariate linkage analysis was not significantly in-
creased, and no significant QTL effect on susceptibility
was observed. Thus, we can not directly replicate the
observation by Hasstedt et al. (2004) of a thrombosis
QTL on chromosome 11. However, lack of statistical
power could be the reason for the failure to confirm
this finding. A biologically plausible candidate gene,
NNMT, is located within this region. NNMT is an en-
zyme involved in the synthesis of SAH, the precursor
of Hcy, and it catabolizes nicotinamide and other pyr-
idine compounds in a reaction that uses the methyl
group generated during the conversion of SAM to SAH
(Aksoy et al. 1994) (fig. 2). NNMT is widely synthesized
in most tissues, especially in the liver (Yan et al. 1999).
An important individual variability in the liver activity
of this enzyme has been described, suggesting a trimodal
distribution (Smith et al. 1998; Yan et al. 1999). In the
absence of functional polymorphisms in the coding re-
gion of NNMT, this distribution has been shown to
depend on variation at mRNA and protein levels (Smith
et al. 1998; Yan et al. 1999).
To test whether NNMT variability accounts for the
observed linkage signal for Hcy plasma levels, we stud-
ied 10 SNPs within this gene. One of them showed
significant association with Hcy levels ( ), al-Pp .017
though this result was no longer significant when cor-
rected for the testing of 10 markers. Moreover, a hap-
lotype built with the 10 SNPs within NNMT was more
strongly associated with higher Hcy levels than were the
remaining haplotypes ( , corrected for mul-Pp .00031
tiple testing). Although we have not yet identified the
functional variants that are responsible for the observed
effects, the significant associations of the intragenic SNP
and haplotype, in conjunction with the linkage signal
in this QTL, strongly support the hypothesis that genetic
variants in NNMT are the main determinants of plasma
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Figure 2 Metabolic pathways involved in Hcy regulation. Enzymes are numbered as follows: (1) methionine adenosyltransferase, (2) SAH
hydrolase, (3) betaine-homocysteine methyltransferase, (4) 5-methyltetrahydrofolate-homocysteine methyltransferase, (5) cystathionine b-syn-
thase, (6) cystathionine g-lyase, (7) serine hydroxymethyltransferase, and (8) 5,10-methylenetetrahydrofolate reductase. B6p vitamin B6; B12p
vitamin B12; CH3 p methyl group; DMG p dimethylglycine; THF p tetrahydrofolate. NNMT is one of at least 39 SAM-dependent methyl-
transferases described in mammals (Clarke and Banfield 2001). The gene encoding NNMT is located on chromosome 11q23, at the same QTL
that has been linked to plasma Hcy levels.
Hcy variability in the GAIT sample. It is very probable
that these variants will be located within noncoding
regions, and they may influence the regulation of tran-
scription. These regions were not included in our se-
quencing because of the huge size of the NNMT gene,
which spans 150 kb. In support of the involvement of
methyltransferases in plasma Hcy concentration, it is
worth mentioning a recent report that demonstrated
that mice deficient in another methyltransferase have a
50% decrease in plasma Hcy (Noga et al. 2003). Thus,
we hypothesize a direct relationship between NNMT
activity and plasma Hcy concentration.
The second-highest LOD score obtained in our ge-
nome scan is located on chromosome 10q22. This locus
contains MATaI, a gene encoding another enzyme in-
volved in Hcy formation (fig. 2). In the context of a
genomewide exploration, a LOD score of 1.68 would
be merely suggestive of linkage, but the presence of an
obvious candidate gene reinforces the necessity of re-
fining the search in this region. We genotyped three
SNPs within MATaI that were reported in 2003 (Celera
database), but none was significantly associated with
Hcy levels (data not shown). Despite the attractiveness
of MATaI as a candidate, the present study did not
prove that it has an effect on Hcy levels. Nevertheless,
an absence of association with some SNPs does not rule
out implication of the gene in determining the pheno-
type. Other SNPs in the same gene that are not in link-
age disequilibrium with those analyzed might be re-
sponsible for the linkage signal.
We have also examined the widely reported influence
of the MTHFR 677 CrT genotype on Hcy levels. First,
we used a two-point linkage analysis to assess the LOD
score between this marker and the phenotype. We also
explored this linkage in the genomewide scan. We con-
firmed previous findings of a direct effect of MTHFR
on Hcy levels (Husemoen et al. 2003; Kluijtmans et al.
2003). However, our results indicate that the MTHFR
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677 CrT polymorphism is not the major genetic de-
terminant of the quantitative variation in Hcy plasma
levels.
In conclusion, we found evidence that the NNMT
gene, located in the region 11q23, influences plasma
Hcy levels. It is probably the major genetic determinant
of this phenotype in the Spanish population. It is pos-
sible that another gene on chromosome 10q22 also in-
fluences Hcy levels. Given the previous reports about
the relevance of Hcy in certain diseases, further studies
are warranted. These should include the exhaustive dis-
section (including exons, introns, and the 5′ and 3′ reg-
ulatory regions) of the NNMT gene. This task will re-
quire a high-throughput resequencing and genotyping
effort, combined with advanced statistical genetic anal-
yses, to determine the most likely functional variants.
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